132 related articles for article (PubMed ID: 28866246)
41. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
42. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up.
Rao Q; Chen JY; Wang JD; Ma HH; Zhou HB; Lu ZF; Zhou XJ
Int J Surg Pathol; 2011 Apr; 19(2):170-9. PubMed ID: 20034980
[TBL] [Abstract][Full Text] [Related]
43. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract][Full Text] [Related]
44. Outcomes of and indications for renal transplantation in patients with von Hippel Lindau disease.
Antony MB; Rompré-Brodeur A; Chaurasia A; Ryan B; Gopal N; Kozel Z; Linehan WM; Ball MW
Urol Oncol; 2023 Dec; 41(12):487.e1-487.e6. PubMed ID: 37778955
[TBL] [Abstract][Full Text] [Related]
45. Percutaneous radiofrequency ablation of renal cell carcinoma.
Chiou YY; Hwang JI; Chou YH; Wang JH; Chiang JH; Chang CY
J Chin Med Assoc; 2005 May; 68(5):221-5. PubMed ID: 15909727
[TBL] [Abstract][Full Text] [Related]
46. CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients.
Thompson LDR; Magliocca KR; Andreasen S; Kiss K; Rooper L; Stelow E; Wenig BM; Bishop JA
Head Neck Pathol; 2019 Sep; 13(3):355-363. PubMed ID: 30291511
[TBL] [Abstract][Full Text] [Related]
47. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
48. Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.
Jilg CA; Neumann HP; Gläsker S; Schäfer O; Leiber C; Ardelt PU; Schwardt M; Schultze-Seemann W
Fam Cancer; 2012 Sep; 11(3):387-94. PubMed ID: 22426863
[TBL] [Abstract][Full Text] [Related]
49. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
[TBL] [Abstract][Full Text] [Related]
50. Percutaneous radiofrequency ablation of small renal cell carcinoma: technique, complications, and outcomes.
Popovic P; Lukic S; Mijailovic M; Salapura V; Garbajs M; Surlan Popovic K
J BUON; 2012; 17(4):621-6. PubMed ID: 23335516
[TBL] [Abstract][Full Text] [Related]
51. Percutaneous Image-Guided Thermal Ablation for Multifocal Renal Cell Carcinoma: 10-Year Experience at a Single Center.
Zhou W; Uppot RN; Feldman AS; Arellano RS
AJR Am J Roentgenol; 2017 Oct; 209(4):733-739. PubMed ID: 28678572
[TBL] [Abstract][Full Text] [Related]
52. Percutaneous ultrasound-guided radiofrequency ablation treatment and genetic testing for renal cell carcinoma with Von Hippel-Lindau disease.
Gao Y; Xu M; Xu ZF; Liu DW; Tu XA; Zheng YL; Wang DH; Sun XZ; Zheng FF; Qiu SP; Lü MD; Zhang YY; Xie XY; Deng CH
J Xray Sci Technol; 2012; 20(1):121-9. PubMed ID: 22398592
[TBL] [Abstract][Full Text] [Related]
53. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
[TBL] [Abstract][Full Text] [Related]
54. Sequential combination treatment (arterial embolization and percutaneous radiofrequency ablation) of inoperable renal cell carcinoma: single-center pilot study.
Nakasone Y; Kawanaka K; Ikeda O; Tamura Y; Yamashita Y
Acta Radiol; 2012 May; 53(4):410-4. PubMed ID: 22393159
[TBL] [Abstract][Full Text] [Related]
55. Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results.
Iwamoto Y; Kanda H; Yamakado K; Soga N; Arima K; Takeda K; Sugimura Y
Fam Cancer; 2011 Sep; 10(3):529-34. PubMed ID: 21503747
[TBL] [Abstract][Full Text] [Related]
56. Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium.
Capitanio U; Rosiello G; Erdem S; Rowe I; Kara O; Roussel E; Campi R; Klatte T; Kriegmair MC; Sibona M; Bertolo R; Ouzaid I; Mir MC; Marra G; Larcher A; Montorsi F; Salonia A;
World J Urol; 2021 Aug; 39(8):2969-2975. PubMed ID: 33416974
[TBL] [Abstract][Full Text] [Related]
57. Radiofrequency ablation (RFA) of T1a renal cancer with externally cooled multitined expandable electrodes.
De Filippo M; Ziglioli F; Russo U; Pagano P; Brunese L; Bertelli E; Pagnini F; Maestroni U
Radiol Med; 2020 Aug; 125(8):790-797. PubMed ID: 32206984
[TBL] [Abstract][Full Text] [Related]
58. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis.
Aarts BM; Gomez FM; Lopez-Yurda M; Bevers RFM; Herndriks J; Beets-Tan RGH; Bex A; Klompenhouwer EG; van der Meer RW
Eur Radiol; 2023 Feb; 33(2):1040-1049. PubMed ID: 36066733
[TBL] [Abstract][Full Text] [Related]
60. Renal cancer in von Hippel-Lindau disease and related syndromes.
Bausch B; Jilg C; Gläsker S; Vortmeyer A; Lützen N; Anton A; Eng C; Neumann HP
Nat Rev Nephrol; 2013 Sep; 9(9):529-38. PubMed ID: 23897319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
